Robot-assisted surgery to remove cancerous prostate glands is effective in controlling the disease for 10 years, according to a new study led by researchers at Henry Ford Hospital.
The study also suggested that traditional methods of measuring the severity and possible spread of the cancer together with molecular techniques might, with further research, help to create personalized, cost-effective treatment regimens for prostate cancer patients who undergo the surgical procedure.
The findings apply to men whose cancer has not spread beyond the prostate, and the results are comparable to the well-established and more invasive open surgery to remove the entire diseased prostate and some surrounding tissue.
The research study is published this month online in European Urology, the official journal of the European Association of Urology.
"Until our analysis, there was little available information on the long-term oncologic outcomes for patients who undergo robot-assisted radical prostatectomy, or RARP," says Mireya Diaz, Ph.D., Director of Biostatistics at the Henry Ford's Vattikuti Urology Institute (VUI) and lead author of the study.
"As one of the very first hospitals to establish a structured RARP program a little over a decade ago, we were able to determine the long-term effectiveness of the technique thanks to the continued feedback of our patients and the follow-up efforts of the VUI team," Dr. Diaz adds.
The researchers followed 483 consecutive men who had cancer that had not spread outside the prostate and received RARP as their first treatment. All cases were from 2001 to 2003, the earliest years of Henry Ford's robot-assisted prostate surgery program.
Using several standard measures of cancer-treatment success – including biochemical markers of recurrence, incidence of metastasis or the spread of cancer beyond the prostate, and cancer-specific survival – the researchers found that 98.8 percent of the patients survived cancer for 10 years after their surgery.
Further analysis showed that the severity of the cancer after RARP was the best predictor of a recurrence, and the level of prostate-specific antigen, or PSA, in the bloodstream – which is now routinely measured as a test for the possible presence of prostate cancer – can be combined with severity to determine future treatment.
"Disease severity and postoperative PSA measurements can guide physicians in identifying the varying levels of cancer recurrence risk," Dr. Diaz explains. "This includes those patients who can best benefit from secondary treatment as well as long-term monitoring."
The study suggests that persistent PSA levels after RARP signals the risk that cancer may progress and soon require a second or salvage treatment of another kind. Lower risk patients after RARP warrant careful monitoring within five years after surgery and more protracted later, while those at higher risk may need follow-up monitoring beyond 10 years.
Further research and the collection of consistent, solid evidence will allow the creation of more personalized regimens for cost-effective treatment following RARP, the study concluded.
Funding: Vattikuti Urology Institute
Copy of the study: http://www.henryford.com/documents/PR/BCR10Yrs_HFHS.pdf
PDF of the study: send email to Dwight.Angell@hfhs.org
Dwight Angell | Eurek Alert!
Diagnoses: When Are Several Opinions Better Than One?
19.07.2016 | Max-Planck-Institut für Bildungsforschung
High in calories and low in nutrients when adolescents share pictures of food online
07.04.2016 | University of Gothenburg
Scientists and engineers striving to create the next machine-age marvel--whether it be a more aerodynamic rocket, a faster race car, or a higher-efficiency jet...
Waveguides are widely used for filtering, confining, guiding, coupling or splitting beams of visible light. However, creating waveguides that could do the same for X-rays has posed tremendous challenges in fabrication, so they are still only in an early stage of development.
In the latest issue of Acta Crystallographica Section A: Foundations and Advances , Sarah Hoffmann-Urlaub and Tim Salditt report the fabrication and testing of...
Electrochemists at TU Graz have managed to use monocrystalline semiconductor silicon as an active storage electrode in lithium batteries. This enables an integrated power supply to be made for microchips with a rechargeable battery.
Small electrical gadgets, such as mobile phones, tablets or notebooks, are indispensable accompaniments of everyday life. Integrated circuits in the interiors...
Recent findings indicating the possible discovery of a previously unknown subatomic particle may be evidence of a fifth fundamental force of nature, according...
A nanocrystalline material that rapidly makes white light out of blue light has been developed by KAUST researchers.
25.08.2016 | Event News
24.08.2016 | Event News
12.08.2016 | Event News
25.08.2016 | Power and Electrical Engineering
25.08.2016 | Health and Medicine
25.08.2016 | Information Technology